Mgmt expression correlates with response rate and survival in patients with inoperable glioblastoma (GBM) treated with neoadjuvant temozolomide (TMZ)

被引：0
|
作者：
Barrie, M.
Eudes, N.
Boucard, C.
Metellus, P.
Fuentes, S.
Honoré, S.
Dufour, H.
Figarella-Branger, D.
Chinot, O.
机构：
[1] CHU Timone, Marseille, France
[2] Fac Med Nord, Marseille, France
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 352
页数：1
相关论文
共 50 条
  • [31] Methylguanine DNA methyl transferase (MGMT) expression to predict response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs)
    Hammel, Pascal
    Hentic, Olivia
    Cros, Jerome
    Rebours, Vinciane
    Zappa, Magaly
    Maire, Frederique
    Ruszniewski, Philippe
    Couvelard, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] MIRNA EXPRESSION, MGMT PROTEIN EXPRESSION AND RESPONSE TO TEMOZOLOMIDE-BASED CHEMOTHERAPY IN GLIOBLASTOMA
    Cipriani, D.
    NEURO-ONCOLOGY, 2016, 18 : 30 - 30
  • [33] A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    James, Allan
    McBain, Catherine
    Jefferies, Sarah
    Harris, Fiona
    Cseh, Agnieszka
    Pemberton, Karine
    Schaible, Jennifer
    Bender, Shaun
    Brada, Michael
    NEURO-ONCOLOGY, 2018, 20 : 20 - 20
  • [34] Combination of Tumor Treating Fields (TTFields) with lomustine (CCNU) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
    Lazaridis, L.
    Kebir, S.
    Weller, J.
    Tzaridis, T. -D
    Scheffler, B.
    Pierscianek, D.
    Kleinschnitz, C.
    Stuschke, M.
    Sure, U.
    Herrlinger, U.
    Schaefer, N.
    Glas, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S109 - S109
  • [35] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Lazaridis, Lazaros
    Schaefer, Niklas
    Kebir, Sied
    Weller, Johannes
    Tzaridis, Theophilos-Dimitrios
    Scheffler, Bjoern
    Pierscianek, Daniela
    Kleinschnitz, Christoph
    Stuschke, Martin
    Sure, Ulrich
    Herrlinger, Ulrich
    Glas, Martin
    NEURO-ONCOLOGY, 2018, 20 : 119 - 120
  • [36] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Lazaridis, L.
    Schaefer, N.
    Kebir, S.
    Weller, J.
    Tzaridis, T.
    Schaeffler, B.
    Pierscianek, D.
    Kleinschnitz, C.
    Stuschke, M.
    Sure, U.
    Herrlinger, U.
    Glas, M.
    NEURO-ONCOLOGY, 2018, 20 : 230 - 230
  • [37] Is long-term survival after glioblastoma multiforme treated by concurrent Temozolomide (TMZ) and radiotherapy possible?
    Micke, O.
    Schaefer, U.
    Schueller, P.
    Willich, N.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 : 142 - 142
  • [38] DOES TIME TO FIRST PROGRESSION (TTP) IMPACT POST-PROGRESSION SURVIVAL IN GLIOBLASTOMA (GBM) IN THE TEMOZOLOMIDE (TMZ) TREATMENT ERA?
    McNamara, Mairead G.
    Lwin, Zarnie
    Jiang, Haiyan
    Chung, Caroline
    Millar, Barbara-Ann
    Sahgal, Arjun
    Laperriere, Normand
    Mason, Warren P.
    NEURO-ONCOLOGY, 2013, 15 : 120 - 120
  • [39] Expression of MGMT and response to treatment with temozolomide in patients with leiomyosarcoma.
    Marrari, A.
    Hornick, J. L.
    Ramaiya, N. H.
    Manola, J.
    Wagner, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Transdermal granisetron is effective in prevention of acute-delayed emesis in patients with glioblastoma multiforme (gbm) treated with temozolomide (tmz): results from a monocentric experience
    Lanzetta, G.
    Corona, M.
    Falbo, P. T.
    Spoto, C.
    Iannace, A.
    De Filippis, L.
    Rozzi, A.
    ANNALS OF ONCOLOGY, 2016, 27
12345